Could cause temporary or reversible harm; serious harm is unlikely.
Failed Dissolution Specifications
| Brand name | BUDESONIDE |
| Generic name | BUDESONIDE |
| Active ingredient(s) | BUDESONIDE |
| Distributed by / for | Actavis Pharma, Inc., Parsippany, NJ 07054 USA |
| NDC | 0591-2510-30 |
| Full product label | Budesonide Extended-Release Tablets 9mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA, NDC 0591-2510-30 |
| Recalling firm | Teva Pharmaceuticals USA, Inc |
| Distribution | Nationwide |
| Quantity | 10,672 30-count bottles |
| Recall initiated | 2024-01-08 |
| Report date | 2024-02-07 |
| Recall completed | — |
| Recall number | D-0275-2024 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Parsippany NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗